Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Forecast to 2030 - Regional Analysis - by Type

The Middle East & Africa cell and gene therapy manufacturing services market is expected to grow from US$ 254.68 million in 2022 to US$ 854.98 million by 2030. It is estimated to grow at a CAGR of 16.3% from 2022 to 2030.

Strategic Initiatives by Companies Drive Middle East & Africa Cell and Gene Therapy Manufacturing Services Market

Companies operating in the Middle East & Africa cell and gene therapy manufacturing services market focus on strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few of the noteworthy developments in the cell and gene therapy manufacturing services market are mentioned below.

• In May 2023, Lonza launched the TheraPEAK T-VIVO Cell Culture Medium with a novel chemically defined formulation devised to optimize and streamline CAR T-cell manufacturing. The TheraPEAK T-VIVO Cell Culture Medium can exhibit a high performance without the need to add human serum or its components, unlike other serum-free media.

• In October 2022, Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd., the manufacturer of NURTEC ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.

• In March 2022, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for paediatric cancers. Under the collaboration, the partners will focus on the BrainChild research program, a suite of five multiplex CARs, to treat pediatric central nervous system (CNS) malignancies. In partnership, they would leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs.

• In March 2022, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Upon collaboration, the companies had plans of combining Twist's antibody libraries with Kriya's proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya's gene therapy technology.

Thus, these strategic initiatives create significant growth opportunities in the Middle East & Africa cell and gene therapy manufacturing services market.

Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Overview

The UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa are major countries in the Middle East & Africa. In June 2022, the United Arab Emirates University (UAEU) researchers had successfully used the gene-editing technology CRISPR-Cas9 to understand disease mechanisms which might provide an opportunity to develop novel therapies. The process of rejuvenation, replacement, regenerating, and restoring cells and restoring healthy function is called regenerative medicine. Regenerative Medicine has already become a strong market in the UAE, and it is expected to grow even more. In healthcare clinics and cities, there are several regenerative medicine options available, especially for musculoskeletal ailments, cardiovascular diseases, and cosmetic dermatology. Several trends in UAE's healthcare sector favour the development of regenerative medicine. The UAE is shifting away from importing drugs and therapeutic products in favour of allocating funds for local drug and therapeutic manufacturing. Government investment in biomedical research and development is also on the rise. This includes advanced biotherapies like cell therapy, immunomodulation therapy, gene therapy, and tissue engineering. Further, in September 2022, Gilead established a fully functional cell therapy business unit and CAR T-Cell therapy operations in Saudi Arabia. Gilead and Kite Middle East launched the “Saudi Arabia's Vision 2030” in which Kite selected Saudi Arabia as the location of its first Middle East operation. The aim of the vision is to establish fully functional oncology/cell therapy business unit in line with international best-in-class protocols for cancer treatment. Thus, aforementioned factors are boosting the growth of Middle East and Africa cell and gene therapy manufacturing services market.

Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Cell and Gene Therapy Manufacturing Services Market Segmentation

The Middle East & Africa cell and gene therapy manufacturing services market is segmented into type, indication, application, end user, and country.

Based on type, the Middle East & Africa cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. In 2022, the cell therapy segment registered a larger share in the Middle East & Africa cell and gene therapy manufacturing services market. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.

Based on indication, the Middle East & Africa cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. In 2022, the cancer segment registered the largest share in the Middle East & Africa cell and gene therapy manufacturing services market.

Based on application, the Middle East & Africa cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. In 2022, the commercial manufacturing segment registered the largest share in the Middle East & Africa cell and gene therapy manufacturing services market.

Based on end user, the Middle East & Africa cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). In 2022, the pharmaceutical and biotechnology companies segment registered a larger share in the Middle East & Africa cell and gene therapy manufacturing services market.

Based on country, the Middle East & Africa cell and gene therapy manufacturing services market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. In 2022, Saudi Arabia registered the largest share in the Middle East & Africa cell and gene therapy manufacturing services market.

Lonza Group AG, Merck KgaA, Nikon Corp, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co LtdĀ are some of the leading companies operating in the Middle East & Africa cell and gene therapy manufacturing services market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa cell and gene therapy manufacturing services market.
• Highlights key in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa cell and gene therapy manufacturing services market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the cell and gene therapy manufacturing services market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution.